AMRN Jan 2025 1.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 03:11PM EDT. Market open.
Loading interactive chart...
- Zacks
Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates
Amarin (AMRN) posts better-than-expected first-quarter 2024 results. Vascepa's sales in the United States continue to be hurt by generic competition.
- GuruFocus.com
Amarin Corp PLC (AMRN) Q1 2024 Earnings: Navigating Challenges with Strategic Focus
Revenue Declines Amidst Generic Competition, Yet Strategic Initiatives Show Promise
- GlobeNewswire
Amarin Reports First Quarter 2024 Business Update and Financial Results
-- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 ‘24 versus Q4 ‘23 Driven by Spain and the UK-- -- Current Cash Position of $308 Million; Remains Stable Over Seven Quarters -- -- Share Repurchase Program of up to $50 Million Approved by Shareholders; Repurchases Expected to Commence Following UK High Court Approval in Second Quarter 2024 -- -- Company to Host
© 2024 Yahoo. All rights reserved.